Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
HOLON, Israel, March 9, 2020 /PRNewswire/ — Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ongoing Phase 1 dose escalation study of COM701 in patients with advanced solid tumors…
Comments Off on Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study